Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

133.21 +2.35 (+1.80%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

76 77 Next >

Exploring the top movers within the S&P500 index during today's session. ↗

April 28, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Incyte (INCY) Q1 Earnings Report Preview: What To Look For

April 28, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results tomorrow morning. Here’s what investors should know.

Via StockStory

Regeneron (REGN) Reports Earnings Tomorrow: What To Expect

April 28, 2025

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know.

Via StockStory

Topics World Trade

Dividend Investor in Mid-50s Making $23,800 A Month Shares Portfolio, Says He Started with $3.50/hour — 'Just 35 Years of Investing' ↗

April 27, 2025

Via Benzinga

Earnings Scheduled For April 24, 2025 ↗

April 24, 2025

Via Benzinga

P/E Ratio Insights for Gilead Sciences ↗

April 23, 2025

Via Benzinga

Why Gilead Sciences Stock Slipped Today ↗

April 25, 2025

Via The Motley Fool

How Is The Market Feeling About Gilead Sciences? ↗

April 25, 2025

Via Benzinga

Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday? ↗

April 25, 2025

Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on U.S.-China trade relations.

Via Benzinga

Get insights into the top movers in the S&P500 index of Friday's pre-market session. ↗

April 25, 2025

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Via Chartmill

AbbVie Reports Upbeat Q1 Earnings, Raises 2025 Earnings Forecast: Retail’s Elated ↗

April 25, 2025

The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira.

Via Stocktwits

Topics World Trade

Gilead Sciences Q1 Earnings Surpass Analyst Expectations, But Revenue Falls Short Of Estimates: Retail’s Optimistic ↗

April 25, 2025

The company is eyeing FDA approval for its drug, lenacapavir, for HIV prevention by mid-June.

Via Stocktwits

Topics Government Stocks

Skechers Posts Weak Revenue, Joins Intel, Gilead Sciences And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

April 25, 2025

Via Benzinga

Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗

April 25, 2025

Via Benzinga

Alphabet, Intel And 3 Stocks To Watch Heading Into Friday ↗

April 25, 2025

Via Benzinga

Which S&P500 stocks are moving after the closing bell on Thursday? ↗

April 24, 2025

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session.

Via Chartmill

Gilead (GILD) Q1 2025 Earnings Call Transcript ↗

April 24, 2025

Via The Motley Fool

Topics Earnings World Trade

Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance ↗

April 24, 2025

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Via Benzinga

Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates

April 24, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance...

Via StockStory

Topics Artificial Intelligence

Gilead Sciences' Bread-And-Butter Drug Missed Sales Views. And It's Not The Only One. ↗

April 24, 2025

Biktarvy sales came in below forecasts. Will Gilead stock be able to shrug it off?

Via Investor's Business Daily

Gilead Sciences Announces First Quarter 2025 Financial Results

April 24, 2025

From Gilead Sciences, Inc.

Via Business Wire

Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday? ↗

April 24, 2025

U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade...

Via Benzinga

Topics Government World Trade

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher ↗

April 24, 2025

BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer.

Via Benzinga

Gilead Sciences's Options Frenzy: What You Need to Know ↗

April 23, 2025

Via Benzinga

Exploring Gilead Sciences's Earnings Expectations ↗

April 23, 2025

Via Benzinga

Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect

April 23, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Assessing Gilead Sciences: Insights From 15 Financial Analysts ↗

April 22, 2025

Via Benzinga

Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer ↗

April 21, 2025

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns.

Via Benzinga

Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved ↗

April 21, 2025

Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence.

Via Stocktwits

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

April 21, 2025

From Gilead Sciences, Inc.

Via Business Wire

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

76 77 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.